Andras Heczey, MD, Baylor College of Medicine, Houston, TX, discusses the trial design and preliminary results from a Phase I trial (NCT04377932) of interleukin-15 armored glypican 3-specific chimeric antigen receptor (AGAR) T cells in pediatric patients with liver cancer. Patients predominantly have hepatoblastoma, with a number of them having hepatocellular carcinoma. The trial assessed the safety of the investigation therapy as well as measured cell expansion and efficacy. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.